ERAS

Erasca, Inc.

2.01 USD
+0.09 (+4.69%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Erasca, Inc. stock is up 16.86% since 30 days ago. The next earnings date is May 26, 2023. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 February’s closed higher than January.

About Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia.